Poltreg (PTG) Investor presentation summary

Strategic positioning and leadership

• Recognized as a global leader in TREG cell therapies, with a strong scientific and business team and over 30% founder ownership.

• Pioneered the first clinical use of TREG-based cell therapy for autoimmune diseases.

• Active participation in major international immunology and diabetes conferences, highlighting scientific leadership.

• Collaboration with top US research institutions, including City of Hope, to expand clinical and commercial reach.

Market opportunity and industry trends

• Type 1 diabetes (T1D) market is growing rapidly, projected to reach $81 billion globally by 2034, with a CAGR of 7.8%.

• High unmet need for causal therapies in autoimmune diseases, driving increased partnering and M&A activity in TREG and cell therapy space.

• Early diagnosis and intervention in T1D are now possible due to advances in screening and new therapies like teplizumab.

Technology and clinical development

• Proprietary PTG-007 technology enables expansion and modification of autologous TREG cells for multiple indications.

• Long-term safety and efficacy of TREG therapy demonstrated in over 100 patients, with up to 12 years of follow-up and no serious adverse events.

• Clinical pipeline includes therapies for both symptomatic and pre-symptomatic T1D, as well as neuroinflammatory and neurodegenerative diseases.

• FDA engagement supports US clinical trials, with potential for accelerated pathways and inclusion of Polish patient data.